中国临床药理学杂志Issue(4)：360-362,3.
伊立替康与拓扑替康单药治疗老年小细胞肺癌的临床研究
Study on treatment with irinotecan and topotecan on small cell lung cancer in elderly patients
韩忠诚 1马丽丽 1柳江 1顾颖2
作者信息
- 1. 新疆维吾尔自治区人民医院 肿瘤科，乌鲁木齐 830001
- 2. 山东电力建设第二工程公司职工医院 内科，济南 250100
- 折叠
摘要
Abstract
Objective To compare the efficacy and safety between irino-tecan (CPT -11) and topotecan (TPT) in the treatment of small cell lung cancer in elderly patients.Methods Data of 39 cases of elderly pathologically confirmed small cell lung cancer ( SCLC ) hospitalized in Xinjiang uygur autonomous region people′s hospital were retrospectively analyzed , in which 22 cases received CPT-11 while the other 17 cases received TPT as chemotherapy .The dose of CPT-11 was 300 mg· m-2 in the first day , and TPT 1.25-1.50 mg· m-2 from the first to the fifth day, 3 weeks was a treatment course .Every patient in two groups accept-ed 2 to 6 periods of chemotherapy ,and the toxicities and curative efficacy were compared between the two groups.Results There was no statisti-cal difference in the curative efficacy or long -term efficacy between the two groups ( P>0.05 ).A higher occurrence rate of leukopenia was ob-served in TPT group compared with the CPT -11 group ( P <0.05 ) , while the ratio of delayed diarrhea showed a reverse result.There were no significant differences in the incidence rates of anemia , thrombocytope-nia, nausea , vomiting and abnormal liver function ( P>0.05 ).Conclu-sion CPT-11 and TPT have similar curative efficacy or long-term ef-ficacy on elderly SCLC patients .The former has more severe gastrointes-tinal reaction , but the latter has more severe hematotoxicity.关键词
伊立替康/拓扑替康/小细胞肺癌/不良反应Key words
irinotecan/topotecan/small cell lung cancer/side-effect分类
医药卫生引用本文复制引用
韩忠诚,马丽丽,柳江,顾颖..伊立替康与拓扑替康单药治疗老年小细胞肺癌的临床研究[J].中国临床药理学杂志,2014,(4):360-362,3.
